## Background: The prognosis associated with malignant pleural mesothelioma (mpm) is poor in spite of surgery, radiotherapy, photodynamic therapy, or chemotherapy. therefore, new therapeutic strategies, including intrapleural immunotherapy, are being investigated. several clinical studies have demo
Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma : A Phase II study
β Scribed by Theodore G. Karrison; Nicholas J. Vogelzang
- Publisher
- John Wiley and Sons
- Year
- 1999
- Tongue
- English
- Weight
- 52 KB
- Volume
- 86
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
β¦ Synopsis
Stage I Renal Cell Carcinoma
I read the report by Kinouchi et al., 1 in which they concluded that the tumor grading of renal cell carcinoma was not predictive of the survival of Robson Stage I patients. This does not mean that the three-grading system is worthless; the authors simply showed that the grading system of the Japanese General Rule for Clinical and Pathological Studies on Renal Cell Carcinoma 2 is not useful in the study of Robson Stage I renal cell carcinoma. The Japanese Rule 2 states that renal cell carcinoma should be classified according to the quantitatively dominant grade. Kinouchi et al. 1 omitted this explanation from their article. This "dominant rule" is obviously distinct from the other grading systems, according to which renal tumor grading is decided by the highest grade. 3,4 I am afraid that their report might mislead international readers. The Japanese General Rule for Clinical and Pathological Studies on Renal Cell Carcinoma 2 was made in 1992. Its classification is different from "modern classification" 5-7 and even from the classification criteria of the Armed Forces Institute of Pathology. 3 Kinouchi et al. 1 nicely demonstrated the limitation of the Japanese Rule. 2 I would like to announce that it is time for the Japanese to throw away their old-fashioned Rule. 2 The recently published protocol of the Cancer Committee of the College of American Pathologists 8 has greater possibilities.
π SIMILAR VOLUMES
## BACKGROUND. Gemcitabine has shown activity in patients with less chemosensitive solid tumors. Phase II screening of novel drugs is an accepted method with which to investigate new therapies in malignant mesothelioma. The European Organization for Research and Treatment of Cancer-Lung Cancer Coo
The purpose of this study was to assess the efficacy and toxicity of a combination of cisplatin and irinotecan (CPT-11) in the treatment of patients with malignant pleural mesothelioma and to characterize the pharmacokinetic profiles of CPT-11 and its active metabolite, 7-ethyl-10-hydroxycamptotheci
## BACKGROUND. Malignant pleural mesothelioma is associated with a poor prognosis because of its resistance to treatment. The authors conducted a Phase II trial in which two drugs (etoposide and 5-fluorouracil) were added to the Cancer and Leukemia Group B cisplatin-mitomycin regimen in an effort t
and cisplatin (P) yielded an objective response rate of 25% and a subjective response rate of 50% in patients with mesothelioma. In human mesothelioma cell